IL-31 monoclonal antibodies

• US 7,531,637 B2
• Filed: 05/08/2006
• Issued: 05/12/2009
• Est. Priority Date: 05/06/2005
• Status: Active Grant

• Current Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Original Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Inventors: Siadak, Anthony W., Bilsborough, Janine, Rene, Shirley
• Primary Examiner(s): MERTZ, PREMA MARIA
• Application Number:
  US11/430,066
• Publication Number:
  US 20060275296A1
• Time in Patent Office: 1,100 Days
• Field of Search: None
• US Class Current: 530/388.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 17/04 Antipruritics
• CPC Class Codes: A61P 17/14 for baldness or alopecia
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/244 Interleukins [IL]
• CPC Class Codes: C07K 2317/21 from primates, e.g. man
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/34 Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C07K 2317/92 Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention further provides the hybridomas that generate the monoclonal antibodies.

Claims

1. A monoclonal antibody that specifically binds a polypeptide comprising the amino acid sequence of SEQ ID NO:

2 wherein the monoclonal antibody is produced by the hybridoma deposited with the American Type Culture Collection having the ATCC Patent Deposit Designation selected from the group consisting of;

a) ATCC Patent Deposit Designation PTA-6815;

b) ATCC Patent Deposit Designation PTA-6816;

c) ATCC Patent Deposit Designation PTA-6829;

d) ATCC Patent Deposit Designation PTA-6830;

e) ATCC Patent Deposit Designation PTA-6831;

f) ATCC Patent Deposit Designation PTA-6871;

g) ATCC Patent Deposit Designation PTA-6872;

h) ATCC Patent Deposit Designation PTA-6875; and

i) ATCC Patent Deposit Designation PTA-6873.

2. The antibody or antibody fragment according to claim 1, wherein the antibody or antibody fragment neutralizes the interaction of a polypeptide comprising SEQ ID NO:

2 from amino acid 27 to amino acid 164 with a receptor polypeptide comprising SEQ ID NO;

5.

3. The antibody or antibody fragment of claim 1, wherein the antibody comprises a radionuclide, enzyme, substrate, cofactor, fluorescent marker, chemiluminescent marker, peptide tag, magnetic particle, or toxin.

4. The antibody or antibody fragment of claim 1, wherein the antibody or antibody fragment comprises PEG.

5. The antibody or antibody fragment of claim 1, wherein the antibody or antibody fragment is a chimeric antibody.

6. The antibody or antibody fragment of claim 1, wherein the antibody or antibody fragment is humanized.

7. A monoclonal antibody or antibody fragment capable of competing with a monoclonal antibody produced by a hybridoma deposited with the American Type Culture Collection having the ATCC Patent Deposit Designation selected from the group consisting of:

a) ATCC Patent Deposit Designation PTA-6815;

b) ATCC Patent Deposit Designation PTA-6816;

c) ATCC Patent Deposit Designation PTA-6829;

d) ATCC Patent Deposit Designation PTA-6830;

e) ATCC Patent Deposit Designation PTA-6831;

f) ATCC Patent Deposit Designation PTA-6871;

g) ATCC Patent Deposit Designation PTA-6872;

h) ATCC Patent Deposit Designation PTA-6875; and

i) ATCC Patent Deposit Designation PTA-6873

for specifically binding to a polypeptide consisting of the amino acid sequence of SEQ ID NO;

2.

8. The monoclonal antibody or antibody fragment according to claim 7, wherein the monoclonal antibody or antibody fragment is produced by the hybridoma deposited with the American Type Culture Collection having the ATCC Patent Deposit Designation PTA-6815.

9. The monoclonal antibody or antibody fragment according to claim 7, wherein the monoclonal antibody or antibody fragment is produced by the hybridoma deposited with the American Type Culture Collection having the ATCC Patent Deposit Designation PTA-6816.

10. The monoclonal antibody or antibody fragment according to claim 7, wherein the monoclonal antibody or antibody fragment is produced by the hybridoma deposited with the American Type Culture Collection having the ATCC Patent Deposit Designation PTA-6829.

11. The monoclonal antibody or antibody fragment according to claim 7, wherein the monoclonal antibody or antibody fragment is produced by the hybridoma deposited with the American Type Culture Collection having the ATCC Patent Deposit Designation PTA-6830.

12. The monoclonal antibody or antibody fragment according to claim 7, wherein the monoclonal antibody or antibody fragment is produced by the hybridoma deposited with the American Type Culture Collection having the ATCC Patent Deposit Designation PTA-6831.

13. The monoclonal antibody or antibody fragment according to claim 7, wherein the monoclonal antibody or antibody fragment is produced by the hybridoma deposited with the American Type Culture Collection having the ATCC Patent Deposit Designation PTA-6871.

14. The monoclonal antibody or antibody fragment according to claim 7, wherein the monoclonal antibody or antibody fragment is produced by the hybridoma deposited with the American Type Culture Collection having the ATCC Patent Deposit Designation PTA-6872.

15. The monoclonal antibody or antibody fragment according to claim 7, wherein the monoclonal antibody or antibody fragment is produced by the hybridoma deposited with the American Type Culture Collection having the ATCC Patent Deposit Designation PTA-6875.

16. The monoclonal antibody or antibody fragment according to claim 7, wherein the monoclonal antibody or antibody fragment is produced by the hybridoma deposited with the American Type Culture Collection having the ATCC Patent Deposit Designation PTA-6873.

17. The monoclonal antibody or antibody fragment of claim 7, wherein administration of the antibody to a mammal inhibits, reduces or blocks production of pro-inflammatory chemokines.

18. The monoclonal antibody or antibody fragment of claim 17, wherein the pro-inflammatory chemokines are TARC or MDC.

19. The monoclonal antibody or antibody fragment of claim 7, wherein administration of the antibody to a mammal inhibits, reduces or blocks scratching.

20. The monoclonal antibody or antibody fragment of claim 7, wherein administration of the antibody to a mammal inhibits, reduces or blocks itch.

21. The monoclonal antibody or antibody fragment of claim 7, wherein administration of the antibody to a mammal inhibits, reduces or blocks dermatitis.

22. The monoclonal antibody or antibody fragment of claim 21, wherein the dermatitis is atopic dermatitis.

23. The monoclonal antibody or antibody fragment of claim 7, wherein administration of the antibody to a mammal inhibits, reduces or blocks hairloss.

24. The monoclonal antibody or antibody fragment according to claim 7, wherein the antibody or antibody fragment neutralizes the interaction of a polypeptide comprising SEQ ID NO:

2 from amino acid 27 to amino acid 164 with a receptor polypeptide comprising SEQ ID NO;

5.

25. The monoclonal antibody or antibody fragment of claim 7, wherein the antibody comprises a radionuclide, enzyme, substrate, cofactor, fluorescent marker, chemiluminescent marker, peptide tag, magnetic particle, or toxin.

26. The monoclonal antibody or antibody fragment of claim 7, wherein the antibody or antibody fragment comprises PEG.

27. The monoclonal antibody or antibody fragment of claim 7, wherein the antibody or antibody fragment is a chimeric antibody.

28. The monoclonal antibody or antibody fragment of claim 7, wherein the antibody or antibody fragment is humanized.

29. A hybridoma, wherein the hybridoma is deposited with the American Type Culture Collection having the ATCC Patent Deposit Designation selected from the group consisting of:

a) ATCC Patent Deposit Designation PTA-6815;

b) ATCC Patent Deposit Designation PTA-6816;

c) ATCC Patent Deposit Designation PTA-6829;

d) ATCC Patent Deposit Designation PTA-6830;

e) ATCC Patent Deposit Designation PTA-6831;

f) ATCC Patent Deposit Designation PTA-6871;

g) ATCC Patent Deposit Designation PTA-6872;

h) ATCC Patent Deposit Designation PTA-6875; and

i) ATCC Patent Deposit Designation PTA-6873.

30. A monoclonal antibody or antibody fragment capable of competing with a monoclonal antibody produced by a hybridoma deposited with the American Type Culture Collection having the ATCC Patent Deposit Designation selected from the group consisting of:

a) ATCC Patent Deposit Designation PTA-6815;

b) ATCC Patent Deposit Designation PTA-6816;

c) ATCC Patent Deposit Designation PTA-6871;

d) ATCC Patent Deposit Designation PTA-6829; and

e) ATCC Patent Deposit Designation PTA-6830

for specifically binding to a polypeptide consisting of the amino acid sequence of SEQ ID NO;

2.

31. A monoclonal antibody or antibody fragment capable of competing with a monoclonal antibody produced by a hybridoma deposited with the American Type Culture Collection having the ATCC Patent Deposit Designation selected from the group consisting of:

a) ATCC Patent Deposit Designation PTA-6815;

b) ATCC Patent Deposit Designation PTA-6816; and

c) ATCC Patent Deposit Designation PTA-6871

for specifically binding to a polypeptide consisting of the amino acid sequence of SEQ ID NO;

2.

32. monoclonal antibody or antibody fragment capable of competing with a monoclonal antibody produced by a hybridoma deposited with the American Type Culture Collection having the ATCC Patent Deposit Designation selected from the group consisting of:

a) ATCC Patent Deposit Designation PTA-6829; and

b)ATCC Patent Deposit Designation PTA-6830

for specifically binding to a polypeptide consisting of the amino acid sequence of SEQ ID NO;

2.

33. A monoclonal antibody or antibody fragment capable of competing with a monoclonal antibody produced by a hybridoma deposited with the American Type Culture Collection having the ATCC Patent Deposit Designation selected from the group consisting of:

a) ATCC Patent Deposit Designation PTA-6872; and

b) ATCC Patent Deposit Designation PTA-6875

for specifically binding to a polypeptide consisting of the amino acid sequence of SEQ ID NO;

2.

34. A monoclonal antibody or antibody fragment capable of competing with a monoclonal antibody produced by a hybridoma deposited with the American Type Culture Collection having the ATCC Patent Deposit Designation selected from the group consisting of:

a) ATCC Patent Deposit Designation PTA-6872;

b) ATCC Patent Deposit Designation PTA-6873;

c) ATCC Patent Deposit Designation PTA-6875; and

d) ATCC Patent Deposit Designation PTA-6831

for specifically binding to a polypeptide consisting of the amino acid sequence of SEQ ID NO;

2.

35. A monoclonal antibody or antibody fragment capable of competing with a monoclonal antibody produced by a hybridoma deposited with the American Type Culture Collection having the ATCC Patent Deposit Designation selected from the group consisting of:

a) ATCC Patent Deposit Designation PTA-6815;

b) ATCC Patent Deposit Designation PTA-6816;

c) ATCC Patent Deposit Designation PTA-6829;

d) ATCC Patent Deposit Designation PTA-6830;

e) ATCC Patent Deposit Designation PTA-6831;

f) ATCC Patent Deposit Designation PTA-6871;

g) ATCC Patent Deposit Designation PTA-6872;

h) ATCC Patent Deposit Designation PTA-6875; and

i) ATCC Patent Deposit Designation PTA-6873

for inhibiting the binding of a polypeptide comprising the amino acid sequence of SEQ ID NO;

2 from residue 27 to residue 164 to a receptor polypeptide comprising the amino acid sequence as shown in SEQ ID NO;

5.

36. The antibody or antibody fragment of claim 35, wherein the antibody or antibody fragment neutralizes the interaction of the polypeptide comprising SEQ ID NO:

2 from amino acid 27 to amino acid 164 with the receptor polypeptide.

37. The antibody or antibody fragment of claim 35, wherein the antibody or antibody fragment comprises a radionuclide, enzyme, substrate, cofactor, fluorescent marker, chemiluminescent marker, peptide tag, magnetic particle, or toxin.

38. The antibody or antibody fragment of claim 35, wherein the antibody or antibody fragment comprises PEG.

39. The antibody or antibody fragment of claim 35, wherein administration of the antibody or antibody fragment to a mammal inhibits, reduces or blocks production of pro-inflammatory chemokines.

40. The antibody or antibody fragment of claim 35, wherein administration of the antibody or antibody fragment to a mammal inhibits, reduces or blocks scratching, itch, dermatitis, or hairloss.

41. The antibody or antibody fragment of claim 40, wherein the dermatitis is atopic dermatitis.

42. The antibody or antibody fragment of claim 35, wherein the antibody or antibody fragment is produced by the hybridoma deposited with the American Type Culture Collection having the ATCC Patent Deposit Designation PTA-6815.

43. The antibody or antibody fragment of claim 35, wherein the antibody or antibody fragment is produced by the hybridoma deposited with the American Type Culture Collection having the ATCC Patent Deposit Designation PTA-6816.

44. The antibody or antibody fragment of claim 35, wherein the antibody or antibody fragment is produced by the hybridoma deposited with the American Type Culture Collection having the ATCC Patent Deposit Designation PTA-6829.

45. The antibody or antibody fragment of claim 35, wherein the antibody or antibody fragment is produced by the hybridoma deposited with the American Type Culture Collection having the ATCC Patent Deposit Designation PTA-6830.

46. The antibody or antibody fragment of claim 35, wherein the antibody or antibody fragment is produced by the hybridoma deposited with the American Type Culture Collection having the ATCC Patent Deposit Designation PTA-6831.

47. The antibody or antibody fragment of claim 35, wherein the antibody or antibody fragment is produced by the hybridoma deposited with the American Type Culture Collection having the ATCC Patent Deposit Designation PTA-6871.

48. The antibody or antibody fragment of claim 35, wherein the antibody or antibody fragment is produced by the hybridoma deposited with the American Type Culture Collection having the ATCC Patent Deposit Designation PTA-6872.

49. The antibody or antibody fragment of claim 35, wherein the antibody or antibody fragment is produced by the hybridoma deposited with the American Type Culture Collection having the ATCC Patent Deposit Designation PTA-6875.

50. The antibody or antibody fragment of claim 35, wherein the antibody or antibody fragment is produced by the hybridoma deposited with the American Type Culture Collection having the ATCC Patent Deposit Designation PTA-6873.

51. The antibody or antibody fragment of claim 35, wherein the antibody or antibody fragment is a chimeric antibody.

52. The antibody or antibody fragment of claim 35, wherein the antibody or antibody fragment is humanized.

53. The antibody or antibody fragment according to claim 35, wherein the antibody or antibody fragment is a Fab molecule or a F(ab'"'"')₂ molecule.

54. The antigen-binding molecule according to claim 35, wherein the antigen-binding molecule is a single-chain molecule.